Viking Therapeutics 過去の業績
過去 基準チェック /06
Viking Therapeuticsの収益は年平均-25.6%で減少しているが、Biotechs業界はgrowingで19%年平均の収益となった。
主要情報
-25.6%
収益成長率
-18.3%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | n/a |
株主資本利益率 | -10.9% |
ネット・マージン | n/a |
前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29収支内訳
収支内訳
Viking Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 24 | 0 | -99 | 43 | 91 |
30 Jun 24 | 0 | -97 | 38 | 87 |
31 Mar 24 | 0 | -94 | 37 | 77 |
31 Dec 23 | 0 | -86 | 37 | 64 |
30 Sep 23 | 0 | -81 | 32 | 59 |
30 Jun 23 | 0 | -74 | 28 | 53 |
31 Mar 23 | 0 | -72 | 22 | 53 |
31 Dec 22 | 0 | -69 | 16 | 54 |
30 Sep 22 | 0 | -62 | 15 | 48 |
30 Jun 22 | 0 | -59 | 13 | 47 |
31 Mar 22 | 0 | -57 | 12 | 46 |
31 Dec 21 | 0 | -55 | 11 | 45 |
30 Sep 21 | 0 | -54 | 10 | 44 |
30 Jun 21 | 0 | -50 | 10 | 41 |
31 Mar 21 | 0 | -44 | 10 | 35 |
31 Dec 20 | 0 | -39 | 11 | 32 |
30 Sep 20 | 0 | -36 | 11 | 29 |
30 Jun 20 | 0 | -32 | 10 | 27 |
31 Mar 20 | 0 | -31 | 10 | 27 |
31 Dec 19 | 0 | -26 | 9 | 24 |
30 Sep 19 | 0 | -24 | 9 | 22 |
30 Jun 19 | 0 | -24 | 8 | 23 |
31 Mar 19 | 0 | -23 | 8 | 20 |
31 Dec 18 | 0 | -22 | 7 | 19 |
30 Sep 18 | 0 | -21 | 7 | 17 |
30 Jun 18 | 0 | -20 | 6 | 15 |
31 Mar 18 | 0 | -19 | 6 | 13 |
31 Dec 17 | 0 | -21 | 5 | 14 |
30 Sep 17 | 0 | -20 | 5 | 13 |
30 Jun 17 | 0 | -18 | 5 | 12 |
31 Mar 17 | 0 | -16 | 5 | 11 |
31 Dec 16 | 0 | -15 | 5 | 9 |
30 Sep 16 | 0 | -16 | 5 | 10 |
30 Jun 16 | 0 | -17 | 6 | 10 |
31 Mar 16 | 0 | -21 | 6 | 9 |
31 Dec 15 | 0 | -23 | 5 | 7 |
30 Sep 15 | 0 | -17 | 4 | 4 |
30 Jun 15 | 0 | -12 | 2 | 2 |
31 Mar 15 | 0 | -27 | 1 | 22 |
31 Dec 14 | 0 | -22 | 1 | 22 |
30 Sep 14 | 0 | -23 | 1 | 22 |
30 Jun 14 | 0 | -23 | 1 | 21 |
31 Mar 14 | 0 | 0 | 0 | 0 |
質の高い収益: VKTXは現在利益が出ていません。
利益率の向上: VKTXは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: VKTXは利益が出ておらず、過去 5 年間で損失は年間25.6%の割合で増加しています。
成長の加速: VKTXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: VKTXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。
株主資本利益率
高いROE: VKTXは現在利益が出ていないため、自己資本利益率 ( -10.88% ) はマイナスです。